Publications by authors named "Emily Gagnon"

The 2022 multicountry mpox outbreak concurrent with the ongoing Coronavirus Disease 2019 (COVID-19) pandemic further highlighted the need for genomic surveillance and rapid pathogen whole-genome sequencing. While metagenomic sequencing approaches have been used to sequence many of the early mpox infections, these methods are resource intensive and require samples with high viral DNA concentrations. Given the atypical clinical presentation of cases associated with the outbreak and uncertainty regarding viral load across both the course of infection and anatomical body sites, there was an urgent need for a more sensitive and broadly applicable sequencing approach.

View Article and Find Full Text PDF

Introduction: The commensal bacterium is a prominent member of the microbiome of animals and humans, and it plays an important role in several physiological processes. Numerous studies have correlated the reduction of abundance with many disease states, including irritable bowel syndrome, Crohn's disease, obesity, asthma, major depressive disorder, and metabolic diseases in humans. Studies have also correlated with diseases in humans involved in altered glucose metabolism, including diabetes.

View Article and Find Full Text PDF
Article Synopsis
  • The 2022 monkeypox outbreak amid the COVID-19 pandemic underscored the essential need for improved genomic surveillance and rapid whole genome sequencing methods.
  • Traditional metagenomic sequencing requires high viral DNA samples and is resource-intensive, prompting the development of a more sensitive approach using PrimalSeq, originally designed for Zika virus, now adapted for monkeypox.
  • Findings showed that amplicon-based sequencing resulted in better genome coverage, especially in samples with lower viral loads, leading to a recommendation of using samples with PCR cycle thresholds below 31 Ct to optimize sequencing efforts.
View Article and Find Full Text PDF

The recent emergence of the SARS-CoV-2 Omicron variant is raising concerns because of its increased transmissibility and its numerous spike mutations, which have the potential to evade neutralizing antibodies elicited by COVID-19 vaccines. Here we evaluated the effects of a heterologous BNT162b2 mRNA vaccine booster on the humoral immunity of participants who had received a two-dose regimen of CoronaVac, an inactivated vaccine used globally. We found that a heterologous CoronaVac prime vaccination of two doses followed by a BNT162b2 booster induces elevated virus-specific antibody levels and potent neutralization activity against the ancestral virus and the Delta variant, resembling the titers obtained after two doses of mRNA vaccines.

View Article and Find Full Text PDF